GSK PLC GSK plc 2024 Annual Report on Form 20-F
March 03 2025 - 11:15AM
RNS Regulatory News
RNS Number : 1635Z
GSK PLC
03 March 2025
Issued: 3 March 2025, London
UK
GSK
plc 2024 Annual Report on Form 20-F
In accordance with Section 203.01 of
the New York Stock Exchange Listed Company Manual, GSK plc ("GSK")
announces that on 3 March 2025 it filed with the Securities and
Exchange Commission an Annual Report on Form 20-F that included
audited financial statements for the year ended 31 December 2024.
GSK's 2024 Annual Report on Form 20-F is available online at GSK's
website at: https://annualreport.gsk.com
and also online at www.sec.gov.
A hard copy version of the GSK 2024
Annual Report, together with the Notice of Annual General Meeting,
will be available on or about 24 March 2025.
Shareholders have the ability to
receive, upon request, a hard copy version of GSK's complete
audited financial statements for the year ended 31 December 2024,
free of charge, by either:
|
(i)
|
writing to Computershare Investor
Services, our registrars in the UK, at the following address:
Computershare Investor Services, The Pavilions, Bridgwater Road,
Bristol BS13 8AE, United Kingdom, or by telephone on +44 (0) 370
707 1595 (please use the country code if calling from outside the
UK);
|
|
(ii)
|
writing to J.P. Morgan Chase Bank,
N.A. our ADR depositary in the US, at the following address: EQ
Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by
telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128
(outside the US); or
|
|
(iii)
|
contacting the GSK Response Center
in the USA at +1 888 825 5249 (US toll free).
|
About GSK
GSK is a global
biopharma company with a purpose to unite science, technology, and
talent to get ahead of disease together. Find out more at
gsk.com.
Victoria Whyte
Company Secretary
3 March 2025
Cautionary statement regarding forward-looking
statements
GSK cautions investors
that any forward-looking statements or projections made by GSK,
including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Such factors include, but are not limited to,
those described under Item 3.D "Risk factors" in GSK's Annual
Report on Form 20-F for 2024.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ACSBRGDXIGGDGUX
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2025 to Mar 2025
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Mar 2025
